AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

Mesenteric tumors are uncommon lesions that are generally considered inclusive of similar lesions of the omentum. These lesions may be cystic or solid, and they may demonstrate malignant or benign clinical behavior. This article discusses mass lesions of the mesentery, including nonprimary tumors with manifestations related to the mesentery.

Primarily anecdotal references to this class of tumors have been made throughout the 20th century. In 1936, Hart provided the earliest clear description of solid mesenteric tumors. As experience has accumulated in treating these lesions, a more complete picture of the various disease types that manifest as mesenteric masses has emerged.

Problem

Although uncommon, mesenteric tumors are encountered in all age groups from infancy to the very elderly. These tumors should be considered as an explanation for a palpable abdominal mass, but they are most commonly brought into the differential diagnosis of abdominal pathology once a suggestive radiologic study or an abdominal operation has been performed. An increased awareness of both neoplastic and nonneoplastic processes that result in mesenteric masses aids the clinician in recognizing these diseases.

Frequency

Solid primary tumors of the mesentery are rare. Published reports have consisted of small numbers of cases, which makes it difficult to determine the incidence of specific tumor types. Reasonable estimates of incidence range from 1 case per 200,000-350,000 population. Mesenteric tumors have been described as cystic in 40-60% of cases.

Numerous anecdotal reports of mesenteric lipomas in adults and children have appeared over the years, suggesting that these probably represent the most frequently encountered symptom-causing solid tumors of primary mesenteric origin.

Malignant primary mesenteric tumors are extremely uncommon, even compared to primary malignancies of the small bowel. Published reports suggest that one third to one half of mesenteric masses are malignant tumors. The largest case series have been from France and China.

These reports indicate that approximately two thirds of malignant mesenteric tumors are mesenchymatous (most characterized as leiomyosarcoma or liposarcoma), while the remainder are primarily lymphomas.

Etiology

No known etiologic or associated diseases have been reported in cases of primary mesenteric neoplasms. Reactive lymphadenopathy within the mesentery may be a manifestation of systemic, often infectious, disease.

Pathophysiology

Clinical findings and symptoms associated with mesenteric tumors of all types are related to the presence of a mass lesion. Because the mass does not involve the tubular portion of the GI tract per se, obstructive symptoms are generally late findings in malignant mesenteric tumors and large benign tumors.

Without question, pain is the principal manifestation of mesenteric masses in adults and older children. A visceral pattern of pain may be related to mass effect within the peritoneum or to traction on the mesentery. This is generally deep and poorly localized discomfort, frequently described as central within the abdomen.

Benign mesenteric masses

These lesions are almost exclusively found in the mesentery of the small intestine, although cysts of the colonic mesentery have also been described. Most are lymphangiomas, but simple peritoneal cysts and enteric cysts are also found, as well as rare mesenteric mesotheliomas with prominent cystic components.

Primary lipoblastoma of the mesentery has been reported in infants and in children as old as 12 years. This benign tumor of fetal-embryonal fat tissue is generally recognized when an abdominal mass is palpated on physical examination and is very amenable to surgical excision, although local recurrence has been described. Other benign neoplasms of the mesentery are exceedingly rare, but tumors of neural origin, hamartomas, and stromal tumors of small size with nonaggressive clinical behavior have been described.

Malignant mesenteric tumors

A relatively few tumor types comprise the vast majority of mesenteric malignancies; of these, the small bowel mesentery is almost exclusively the site of involvement.

Primary malignant mesenchymal or stromal tumors of the mesentery of the bowel, as well as of the greater and lesser omentum, are a rare subset of abdominal cancers that resemble either retroperitoneal sarcomas or gastrointestinal stromal tumors (GISTs) primary to the intestine. Most of these have been described as leiomyosarcomas. Miettinen et al reported that, in a group of 26 cases analyzed by the Armed Forces Institute of Pathology, the incidence of omental and mesenteric tumors was roughly equal.

Characterization of protein markers of this tumor type has indicated that they are phenotypically very similar to the GIST group and are less frequently phenotypically related to retroperitoneal leiomyosarcomas. The absence of a detectable primary intestinal tumor signifies a primary mesenteric origin of the lesion.

Patients with mesenteric tumors exhibit signs and symptoms of intestinal obstruction; however, in contrast to primary tumors of the intestine, much bulkier disease may be present before obstructive findings are encountered.

Desmoid tumors of the mesentery

Mesenteric desmoid tumors are a relatively infrequent but potentially life-threatening complication of familial adenomatous polyposis (FAP). These tumors are areas of progressive fibroblastic and fibrous proliferation within the mesentery (and less frequently, the retroperitoneum) that can locally involve vascular structures and can constrict and obstruct the bowel. Although described as histologically benign lesions, their infiltrative pattern of growth can ultimately lead to life-threatening patterns of visceral involvement.

Sporadically occurring desmoid tumors are more numerous than those observed in FAP, although the cumulative risk of the development of these lesions is far greater in patients with FAP. Mesenteric desmoid tumors were originally reported as a component of Gardner syndrome, a phenotypic pattern of FAP that, in addition to intestinal adenomatous polyps, is also associated with bony abnormalities, pigmented ocular fundus lesions, and cutaneous epidermoid cysts and fibromas. That such arbitrary classifications are not necessarily valid is now apparent.

Although a causative relationship in desmoid formation has not been firmly established, various mutations of the APC gene have been identified in these tumors. Desmoid tumors are more frequently associated with disease-causing mutations distal to codon 1444 of the APC gene.

Primary mesenteric lymphoma, in contrast to primary small bowel lymphoma, is a disease of the mesenteric lymph nodes that may represent a localized process or a component of a more disseminated pattern of disease. The clinical presentation of mesenteric lymphoma is much like that of other mesenteric tumors, with abdominal pain and palpable mass as the principal findings.

CT scans can characterize the lesion from the standpoint of size and mesenteric location and can raise the probability of the lymphoma diagnosis. The follicular centroblastic-centrocytic histologic type of lymphoma has been shown to predominate at mesenteric sites. A few cases of mesenteric lymphomas observed in association with immune thrombocytopenia and dermatitis herpetiformis have been reported.

The vast majority of metastatic lesions of the mesentery consist of mesenteric lymph nodes that have become secondarily involved in a neoplastic process of the tubular GI tract. Distinguishing this pattern of tumor growth from primary mesenteric tumors usually presents no difficulty because the GI primary tumor site is usually readily identifiable.

Carcinoid tumors of the small intestine are metastatic to mesenteric lymph nodes at the time of diagnosis in 40-50% of patients, although almost all of such tumors greater than 2 cm in diameter have associated nodal involvement. Of these, a small subset may have minimal obvious disease within the small intestine and large mesenteric nodal metastases that may comprise the vast majority of the tumor burden. In addition, primary mesenteric carcinoids have been described that have been assumed to arise de novo in mesenteric tissues, although the veracity of this assumption is uncertain.

This pattern of disease may be accompanied by extrinsic compression and occlusion of mesenteric arterial blood supply and segmental ischemia or infarction of the intestine. Extensive carcinoid tumor involvement of small bowel mesentery has been reported in association with a malabsorption syndrome.

Mesenteric lipodystrophy

Mesenteric lipodystrophy (retractile mesenteritis, mesenteric panniculitis) is a rare condition that can be mistaken for a mesenteric neoplasm based on clinical, radiologic, and gross characteristics. It is a mesenteric thickening or mass that can be nodular in consistency and either focal or diffuse within the small intestinal mesentery. The root of the mesentery and the tissues surrounding the superior mesenteric vessels are invariably involved.

The mass may consist of hypertrophied fatty tissue, dense fibrous tissue, fat necrosis, or combinations of these, along with a nonspecific chronic inflammatory infiltrate. Its presenting symptom is abdominal pain in most patients, although it has been anecdotally reported in association with fever, mesenteric calcifications, and protein-losing enteropathy.

The causative agents are unknown, although an association with lymphoma has been reported. Current data indicate that the condition is nonprogressive and presents no significant danger to the patient.

Treatment is nonsurgical (although the diagnosis is confirmed on operative biopsy) and generally supportive. In patients with more severe symptoms, antimetabolites such as cyclophosphamide have been associated with both a decrease in lesion size and symptom relief. Other reportedly beneficial agents include steroids, colchicine, and tamoxifen.

Mesenteric lymphadenopathy

Infectious etiologies of mesenteric lymph node enlargement include bacterial infection, Mycobacterium, and histoplasmosis. A large number of these cases have been reported since the onset of the HIV epidemic. Although lymphadenopathy is usually generalized in tuberculosis, mesenteric lymphadenitis has been described as the principal presenting problem.

Castleman disease (giant lymph node hyperplasia) is a rare condition usually observed in the mediastinum. However, cases of isolated mesenteric disease have been reported. These primarily occur in women and can be associated with iron malabsorption and anemia. Sarcoid has been reported as a cause of localized bulky mesenteric lymphadenopathy.

Clinical

Pain is the principal presenting symptom resulting in the discovery of a mesenteric mass. A palpable mass may also be present, although generally not without some abdominal pain. Nausea, vomiting, diarrhea, bloating, and constipation have also been described with mesenteric tumors.

Although most symptoms reflect a fairly indolent process, intestinal obstruction has been reported with both benign and malignant mesenteric tumors. In the case of malignant tumors, this is generally secondary to aggressive local growth. In the case of benign tumors such as lipoma, the pathophysiology of obstruction is more complex.

Published descriptions of obstruction with mesenteric lipoma have implicated small intestinal encasement, small bowel volvulus, or tumor infarction and obstruction due to the consequent inflammatory mass. Acute appendicitis as the result of torsion of a mesoappendiceal lipoma has also been described.

Clinical examination may reveal an abdominal mass. In the case of mesenteric lipoma, the tumor frequently cannot be appreciated by palpation.

In the case of mesenteric cysts, physical examination findings may reveal a mass lesion that is mobile only from the patient's right to left or left to right (Tillaux sign), in contrast to the findings with omental cysts, which should be freely mobile in all directions.

INDICATIONS

Section 3 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

The presence of any solid mass lesion of the mesentery that is not thought to be a reactive lymph node or lymphoma is an indication for surgical removal. The inability to definitively exclude malignancy makes prolonged observation and repetitive studies an ill-advised management strategy. In selected circumstances, biopsy is indicated to help confirm the diagnosis of certain lesions. For example, lymphoma might represent a likely diagnosis based on radiologic findings. If no other more readily accessible tissues were available, it would be necessary to obtain mesenteric tissue to guide therapy. A small simple cyst of the mesentery discovered incidentally can be observed. In the setting of interval enlargement, significant symptoms (generally pain), or evolution of symptoms, surgical excision is advisable for simple cysts as well. Complex cystic structures related to the omentum must prompt consideration of the possibility of a neoplastic process.

RELEVANT ANATOMY

Section 4 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

The mesentery of the GI tract consists of a contiguous fibrofatty fanlike structure containing arterial, venous, lymphatic, and neural structures coursing to and from the entire length of the intestine. The small intestinal mesentery and portions of the large intestinal mesentery are mobile within the peritoneal cavity. The mesenteries of the ascending and descending colon become fixed against the retroperitoneum during the normal course of fetal development. The lesser omentum is also technically a mesentery, and any consideration of tumors of these structures is generally inclusive of lesions of the greater omentum as well. The vast majority of reported mesenteric tumors originate in the small bowel mesentery or omentum.

WORKUP

Section 5 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

Lab Studies

• Specific lab studies are not usually helpful in characterizing mesenteric tumors.

Imaging Studies

• Abdominal CT scans: Radiologic characterization of malignant mesenteric tumors generally requires a CT scan, which can provide important information regarding size and involvement of adjacent structures, as well as some tissue characteristics of the tumor. The localization of a mass to mesentery is generally possible with this study. CT scanning can also distinguish between solid and cystic masses and can identify hepatic metastases in the presence of advanced malignant disease.

  Abdominal CT scans can be very suggestive of the diagnosis of lipoma as opposed to other solid tumors, although liposarcoma cannot be completely excluded based on CT scan appearance. These lesions are of fat density and may surround mesenteric vessels and lymph nodes. To some extent, tumor vascularity can also be characterized with the administration of intravenous contrast during imaging.

• MRI: MRI is sometimes used in conjunction with CT scanning to help characterize mesenteric masses. It provides similar information to CT scanning but can also define tissue characteristics (ie, fatty vs fibrous) with greater sensitivity. No data compare the two studies in the examination of mesenteric masses; however, MRI may be of great value, particularly in patients with mesenchymal tumors.
• Arteriography: Arteriography is seldom used as a preoperative study in patients with mesenteric tumors unless there is a significant possibility that vascular involvement by the tumor may greatly complicate operative management. This procedure may define areas of mesenteric arterial blood supply that are compromised by tumor and may suggest the need for either extensive bowel resection with the mesenteric mass or arterial reconstruction.
• Ultrasound: The successful use of ultrasound to characterize mesenteric masses is well described. Ultrasound is used far less frequently than CT scanning, largely because of operator-dependent issues that can influence study consistency.

TREATMENT

Section 6 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

Medical therapy

• In general, effective medical treatment of neoplastic mesenteric masses is not available. Pain and other GI complaints can be treated with analgesics and antiemetics, but these agents do not affect the underlying disease.
• Mesenteric lymphoma is treated by cytotoxic chemotherapy.
• Mesenteric desmoid tumors reportedly respond to Sulindac therapy, hormonal manipulation, and cytotoxic chemotherapy.

Surgical therapy

• In general, surgical treatment of benign mesenteric masses consists of local excision for smaller lesions and resection for bulkier tumors, provided the blood supply to the gut is not jeopardized.
• Although the bowel can be preserved in most circumstances, resection can be quite treacherous, depending on the relationship of the lesion to larger branches of the superior mesenteric artery.
• Most cystic mesenteric lesions can be easily excised. Resection of small intestine is rarely indicated for this problem.

Malignant mesenteric tumors

Surgical treatment is the only therapy of demonstrated benefit for these tumors. The goal of surgical treatment is removal of gross disease with a margin of normal tissue. This requires resection of any involved intestine, as well as of intestine robbed of mesenteric arterial blood supply by the dissection to remove the tumor. As in the treatment of intestinal stromal tumors or retroperitoneal sarcomas, operative management may involve en bloc resection of other involved structures.

Mesenteric desmoid tumors

These are very difficult lesions to treat surgically. Surgical treatment may increase recurrence risk because it has been observed that desmoid tumors generally occur following abdominal surgery. Surgical debulking may be dangerous and ultimately unsuccessful and is generally reserved for patients with intestinal obstruction.

Mesenteric lymphoma

In contrast to primary small bowel lymphoma, in which surgical treatment may play a valuable role in selected cases, mesenteric lymphoma is best treated with combination chemotherapy. Although some cases are diagnosed following resection of an uncharacterized mesenteric mass, surgical treatment is best used as a diagnostic tool when the diagnosis is probable but uncertain. Laparoscopy may play an important role when the procurement of tissue for diagnostic purposes is the operative goal.

Mesenteric carcinoid tumor

The treatment of this pattern of disease is to surgically resect the mesenteric masses. This procedure should be performed en bloc with any extant primary intestinal tumor. Resection of mesenteric disease should be accomplished without endangering the blood supply to normal bowel, except in the immediate area of the disease. A primary carcinoid tumor, which may be quite small and multicentric, is generally found in the resected intestinal specimen.

Castleman disease

Because this problem is nonneoplastic and generally localized, treatment has consisted of resection of the lymph node mass with good results.

Intraoperative details

At exploration, the mass is generally found completely contained within the mesentery. In the case of liposarcoma, encasement of the bowel with fatty tumor tissue can occur. The gross extent of the tumor must be carefully defined in order to obtain clear margins of resection. Definition of proximity to large mesenteric blood vessels is vital. Normal intestine should be preserved to the greatest extent possible while still observing good oncologic surgical principles. If resection requires so much intestine be removed that nutrition cannot be expected to be maintained, the patient's clinical situation (eg, age, general health) must be taken into consideration before proceeding.

COMPLICATIONS

Section 7 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

Complications of surgical treatment of mesenteric masses are not specific to the disease type, except when extensive resection of solid tumors may either endanger mesenteric blood supply or when extensive small bowel resection is necessary to remove the disease. Although an infrequent occurrence in surgery involving the mesentery, the appropriate precautions must be taken to prevent short-bowel syndrome, either as the result of overresection or inadvertently damaging the blood supply to otherwise normal bowel.

OUTCOME AND PROGNOSIS

Section 8 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

The results of surgical treatment of benign cysts and solid tumors of the mesentery are very favorable. This is true of even large benign tumors, although local recurrence has been reported. Death as a consequence of benign masses, with the exception of mesenteric desmoid tumors, can be assumed to be an extremely unlikely event.

Because so few have been reported, long-term results of surgical treatment of malignant mesenteric mesenchymal tumors is not well characterized. In fact, no large series reporting management and outcomes of treatment of this tumor type have been conducted. Published reports suggest similar biologic behavior to primary GI mesenchymal malignancies. Reported sites of hematogenously spread metastases include the liver and lungs.

Extrapolating the results of treatment of similarly staged GI stromal malignancies suggests that 5-year survival rates are in the range of 20-50%. No specific postoperative adjuvant or palliative therapies, such as cytotoxic chemotherapy or radiation therapy, have been shown to be of benefit.

Intra-abdominal desmoid tumors are the second most frequent cause of death in FAP patients (after cancer-related deaths).

FUTURE AND CONTROVERSIES

Section 9 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

The use of laparoscopic methods to investigate and treat mesenteric masses is an evolving area of surgical care. In patients whose disease must only be distinguished from that requiring resection (ie, lymphoma, mesenteric lipodystrophy), laparoscopy offers a method of obtaining tissue for diagnostic purposes without subjecting the patient to a full laparotomy incision.

MULTIMEDIA

Section 10 of 11  

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

Media file 1:  Mesenteric lipoma. This small, well-circumscribed lesion of the small bowel mesentery caused no symptoms and was incidentally discovered at operation.
	View Full Size Image
Media type:  Photo

Media file 2:  CT scan of mesenteric stromal tumor (circled area). This is an infiltrative lesion surrounding vascular structures within the proximal jejunal mesentery.
	View Full Size Image
Media type:  CT

Media file 3:  Resected mesenteric liposarcoma specimen. This firm, fatty mass replaced a large segment of small bowel mesentery and surrounded a short segment of ileum (lower edge of specimen). The principal presenting problem was partial small bowel obstruction.
	View Full Size Image
Media type:  Photo

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Indications
• Relevant Anatomy
• Workup
• Treatment
• Complications
• Outcome and Prognosis
• Future and Controversies
• Multimedia
• References

• Andersson H, Dotevall G, Mobacken H. Malignant mesenteric lymphoma in a patient with dermatitis herpetiformis, hypochlorhydria, and small-bowel abnormalities. Scand J Gastroenterol. 1971;6(5):397-9. [Medline].
• Aspestrand F, Pollard L. Carcinoid infiltration and fibroplastic changes of the mesentery as a cause of malabsorption. Radiologe. Feb 1986;26(2):79-81. [Medline].
• Barnardo DE, Stavrou M, Bourne R. Primary carcinoid tumor of the mesentery. Hum Pathol. Aug 1984;15(8):796-8. [Medline].
• Bauernhofer T, Stoger H, Schmid M. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer. Mar 15 1996;77(6):1061-5. [Medline].
• Bersack SR, Iovine VM, Theosky G. Lipomas of the mesentery of the small bowel. Radiology. 1951;56:850-855.
• Bjarnason I, Cotes PM, Knowles S. Giant lymph node hyperplasia (Castleman''s disease) of the mesentery. Observations on the associated anemia. Gastroenterology. Jul 1984;87(1):216-23. [Medline].
• Bush RW, Hammar SP Jr, Rudolph RH. Sclerosing mesenteritis. Response to cyclophosphamide. Arch Intern Med. Mar 1986;146(3):503-5. [Medline].
• Caspari R, Olschwang S, Friedl W. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. Mar 1995;4(3):337-40. [Medline].
• Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis [see comments]. Br J Surg. Nov 1996;83(11):1494-504. [Medline].
• Clouse ME, Harrison DA, Grassi CJ. Lymphangiography, ultrasonography, and computed tomography in Hodgkin''s disease and non-Hodgkin''s lymphoma. J Comput Tomogr. Jan 1985;9(1):1-8. [Medline].
• Dougherty MJ, Compton C, Talbert M. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. Nov 1991;214(5):569-74. [Medline].
• Emory TS, Monihan JM, Carr NJ. Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity?. Am J Surg Pathol. Apr 1997;21(4):392-8. [Medline].
• Fazzi P, Solfanelli S, Morelli G. Sarcoidosis: single bulky mesenteric lymph node mimicking a lymphoma. Sarcoidosis. Mar 1995;12(1):75-7. [Medline].
• Gonzalez-Crussi F, deMello DE, Sotelo-Avila C. Omental-mesenteric myxoid hamartomas. Infantile lesions simulating malignant tumors. Am J Surg Pathol. Sep 1983;7(6):567-78. [Medline].
• Guivarc''h M. [Tumors of the mesentery. Apropos of 102 cases]. Ann Chir. 1994;48(1):7-16. [Medline].
• Gurbuz AK, Giardiello FM, Petersen GM. Desmoid tumours in familial adenomatous polyposis. Gut. Mar 1994;35(3):377-81. [Medline].
• Hardisson D, Limeres MA, Jimenez-Heffernan JA. Solitary fibrous tumor of the mesentery. Am J Gastroenterol. Apr 1996;91(4):810-1. [Medline].
• Hart JT. Solid tumors of the mesentery. Ann Surg. 1936;104:184-198.
• Hashimoto H, Tsuneyoshi M, Enjoji M. Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases. J Surg Oncol. Mar 1985;28(3):177-86. [Medline].
• Hemaidan A, Vanegas F, Alvarez OA. Mesenteric lipodystrophy with fever of unknown origin and mesenteric calcifications. South Med J. May 1999;92(5):513-6. [Medline].
• Jimenez JF. Lipoblastoma in infancy and childhood. J Surg Oncol. Aug 1986;32(4):238-44. [Medline].
• Jones IT, Jagelman DG, Fazio VW. Desmoid tumors in familial polyposis coli. Ann Surg. Jul 1986;204(1):94-7. [Medline].
• Killam AR. An unusual cause of appendicitis: torsion produced by a mesoappendiceal lipoma. Am Surg. Sep 1969;35(9):648-9. [Medline].
• Kimura H, Yonemura Y, Kadoya N. Prognostic factors in primary gastrointestinal leiomyosarcoma: a retrospective study. World J Surg. Nov-Dec 1991;15(6):771-6; discussion 776-7. [Medline].
• Kipfer RE, Moertel CG, Dahlin DC. Mesenteric lipodystrophy. Ann Intern Med. May 1974;80(5):582-8. [Medline].
• Kurtz RJ, Heimann TM, Holt J. Mesenteric and retroperitoneal cysts. Ann Surg. Jan 1986;203(1):109-12. [Medline].
• Livne PM, Zer M, Shmuter Z. Acute intestinal obstruction caused by necrotic mesenteric lipoma--a case report. Am J Proctol Gastroenterol Colon Rectal Surg. Nov 1981;32(11):19-22. [Medline].
• Luo HS. [Mesentery tumor--clinico-pathologic analysis of 171 cases]. Chung Hua Chung Liu Tsa Chih. Mar 1989;11(2):139-41. [Medline].
• McGrath PC, Neifeld JP, Lawrence W Jr. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg. Dec 1987;206(6):706-10. [Medline].
• Miettinen M, Monihan JM, Sarlomo-Rikala M. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. Sep 1999;23(9):1109-18. [Medline].
• Miyaki M, Tanaka K, Kikuchi-Yanoshita R. Familial polyposis: recent advances. Crit Rev Oncol Hematol. Apr 1995;19(1):1-31. [Medline].
• Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. Oct 1987;5(10):1502-22. [Medline].
• Moriwaki Y, Naka M, Yamamoto T. Malignant lymphoma in the mesentery with immune thrombocytopenia. Intern Med. Oct 1992;31(10):1185-9. [Medline].
• Munk PL, Lee MJ, Poon PY. Computed tomography of retroperitoneal and mesenteric sarcomas: a pictorial essay. Can Assoc Radiol J. Oct 1996;47(5):335-41. [Medline].
• Pantongrag-Brown L, Buetow PC, Carr NJ. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am J Roentgenol. Feb 1995;164(2):387-91. [Medline].
• Petrik PK. Fatal small intestinal infarction due to occlusion by mesenteric carcinoid tumor. Am J Forensic Med Pathol. Jun 1989;10(2):146-8. [Medline].
• Prando A, Wallace S, Marins JL. Sonographic features of benign intraperitoneal lipomatous tumors in children--report of 4 cases. Pediatr Radiol. 1990;20(8):571-4. [Medline].
• Rosen L, Fried G. Annular lipoma of the mesentery as an unusual cause of small bowel obstruction. Mt Sinai J Med. Mar-Apr 1981;48(2):140-1. [Medline].
• Signer RD, Bregman D, Klausner S. Giant lipoma of the mesentery: report of an unusual case and review of the literature. Am Surg. Aug 1976;42(8):595-7. [Medline].
• Tahlan RN, Garg P, Bishnoi PK. Mesenteric lipoma: an unusual cause of small intestinal volvulus. Indian J Gastroenterol. Oct 1997;16(4):159. [Medline].
• Takahashi T, Kuwao S, Yanagihara M. A primary solitary tumor of the lesser omentum with immunohistochemical features of gastrointestinal stromal tumors. Am J Gastroenterol. Nov 1998;93(11):2269-73. [Medline].
• Vanek VW, Phillips AK. Retroperitoneal, mesenteric, and omental cysts. Arch Surg. Jul 1984;119(7):838-42. [Medline].
• Yannopoulos K, Stout AP. Primary solid tumors of the mesentery. Cancer. 1963;16:914.
• Zanetti G. Benign lipoblastoma: first case report of a mesenteric origin. Tumori. Aug 31 1988;74(4):495-8. [Medline].
• van Krieken JH, Otter R, Hermans J. Malignant lymphoma of the gastrointestinal tract and mesentery. A clinico-pathologic study of the significance of histologic classification. NHL Study Group of the Comprehensive Cancer Center West. Am J Pathol. Aug 1989;135(2):281-9. [Medline].

Article Last Updated: Apr 12, 2006